Patient‐reported outcomes (<scp>PRO</scp>s) in chronic urticaria

Moestrup, Kristian; Ghazanfar, Misbah Nasheela; Thomsen, Simon Francis

doi:10.1111/ijd.13668

Cited by 21 publications

(32 citation statements)

References 44 publications

(80 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The CU-Q2oL provides detailed information on the effects of CU on different QoL domains, and it can be useful to compare changes over time including those that occur in response to different treatments. On the other hand, it is generally considered to be more time consuming than other PRO measures, both for patients as well as physicians 19 . Our findings are consistent with a European study that reported low use (approximately 50% of patients) of the CU-Q2oL at baseline evaluation 21 …”

Section: Discussionsupporting

confidence: 90%

“…The higher reported use of UCT in our patients, compared to UAS7 and CU-Q2oL, might be the result of the former being simpler and faster to use among physicians and patients 19 . On the other hand, CU-Q2oL was the least used PRO at baseline (approximately 37.5%), with a similar low overall use throughout the patients’ follow up.…”

Section: Discussionmentioning

confidence: 67%

“…Our study provides real-life data on the timing and dosing of omalizumab in the treatment of CU patients as well as on the use of PRO measures for assessing their clinical response 16, 17, 18. Currently, there are no reliable biomarkers to identify and measure disease activity in CU 19 . Consequently, the use of PRO instruments remains crucial to evaluate and monitor various aspects of CU including activity, severity, control, and quality of life 19 .…”

Section: Discussionmentioning

confidence: 99%

“…Currently, there are no reliable biomarkers to identify and measure disease activity in CU 19 . Consequently, the use of PRO instruments remains crucial to evaluate and monitor various aspects of CU including activity, severity, control, and quality of life 19 . Among the available PRO instruments, UAS7 has been considered the gold standard and has been extensively used in clinical trials 20 .…”

Section: Discussionmentioning

confidence: 99%

“…It is well known that improvement in disease activity does not always translate to better quality of life. CSU disease activity assessed by UAS7 is a significant predictor for overall CU-Q2oL score, but patients with a low UAS7 score may still have markedly impaired quality of life 19, 32. This highlights the importance of assessing CU patients with multiple tools in order to achieve a more complete status of disease impact.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America

Chérrez-Ojeda

Maurer

Bernstein

et al. 2019

World Allergy Organization Journal

View full text Add to dashboard Cite

Background Updated urticaria guidelines recommend that patients should be assessed for disease activity, severity, control, and quality of life at baseline and follow up. Regarding treatment, guidelines consider second generation antihistamines as the cornerstone in therapy for chronic urticaria (CU), while other drugs, such as omalizumab, are conceived as second-line alternatives. In regards to omalizumab, despite advances in the management of CU, there are still open questions about timing, dosing, and objective measures for clinical response. This study was designed to portray the use of patient-reported outcomes (PROs) in chronic urticaria management, as well as the effectiveness and treatment patterns of omalizumab in CU, as seen in a real-life setting in Latin America. Methods This is a retrospective observational study, involving 72 Latin American patients with chronic urticaria treated with omalizumab. Patient reported outcomes and treatment patterns, response, quality of life improvement and discontinuation were analyzed. Results From the 72 patients, 91.7% (n = 66) were assessed through PROs, where urticaria control test (UCT) was the most used (79.2%; n = 57). Overall, 80.0% (n = 44) responded to omalizumab at some point of the treatment. Omalizumab 300 mg was associated with earlier response compared to lower doses. Regardless of dosage, most patients assessed with CU-Q2oL improved quality of life (80.8%; n = 21). With respect to omalizumab discontinuation, 20.8% (n = 15) patients interrupted omalizumab before the 3rd month of treatment (p = .000). Conclusions The present study highlights how the use of PROs and omalizumab in Latin America differ from guidelines’ recommendations and clinical trials. Even though most patients were initiated under omalizumab 300 mg, most of them finished with lower doses. Regardless of dosage, most patients responded to omalizumab and improved quality of life at some point during treatment. However, such features were seen earlier with omalizumab 300 mg. Regarding treatment discontinuation, one-fifth of patients interrupted omalizumab before the third month.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 67%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America

Chérrez-Ojeda

Maurer

Bernstein

et al. 2019

World Allergy Organization Journal

View full text Add to dashboard Cite

show abstract

Chronic Spontaneous Urticaria: How to Measure It and the Need to Define Treatment Success

Armstrong

Soong

Bernstein

2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Chronic spontaneous urticaria (CSU) is a complex skin disease characterized by the spontaneous appearance of wheals, angioedema, or both, for more than 6 weeks. Many patients experience a relapsing–remitting disease course for years. Owing to the unpredictability of wheal recurrence and the severity of pruritis, patients suffer considerable impairment in their quality of life. Physicians face multiple challenges, not least of which is a lack of clear guidance on what constitutes “treatment success”. There is a lack of awareness of which measures should be used to best assess the various aspects of CSU, including disease activity, disease control, and quality of life—which themselves each comprise multiple components—and how to apply the results of each score to treatment decision-making. Although the overarching aim of treatment is for patients to be completely free of signs and symptoms of CSU, a more realistic definition of “treatment success” is needed to guide ongoing, long-term disease management for each individual patient. In this review, we consider what lessons can be learned from the current evidence base to provide further direction toward a universal definition of “treatment success”.

show abstract

Acute and Chronic Urticaria Diagnosis and Management Taking into Account Their Differences

Salman

Mohammad‐Porras

Arnau

2023

Curr Treat Options Allergy

View full text Add to dashboard Cite

Purpose of review Urticaria is a frequent disorder that can present with erythema, edema, and pruritus involving the skin and mucous membranes. Early diagnosis and proper management of the urticaria according to the type (i.e., acute vs chronic) is of utmost importance to reduce the burden of the disease and prevent psychosocial comorbidities. In this review, we aim to summarize the diagnosis and management of acute and chronic urticaria with emphasis on the differences. Recent findings Autoimmune mechanisms (type I or type IIb autoimmunity) have been recently defined in the pathogenesis of chronic spontaneous urticaria. Despite the high rates of symptom control in both acute and chronic urticaria with the existing treatment options, new treatments are still needed in a subset of patients. Promising treatment targets in CSU include Bruton’s tyrosine kinase, Siglec-8, or IL-4/13. Summary Therapeutic management of acute and chronic urticaria is still challenging despite the highly effective treatments. In addition to symptomatic treatment, elicitation of the pathogenesis of both forms of urticaria and clear understanding of the nature of the disease by the patient are essential. Urticaria has still a high impact on the patients’ quality of life warranting the studies on the pathogenesis, novel treatment options, and the factors determining which patients with acute urticaria will likely develop chronic urticaria.

show abstract

Patient‐reported outcomes (PROs) in chronic urticaria

Cited by 21 publications

References 44 publications

Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America

Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America

Chronic Spontaneous Urticaria: How to Measure It and the Need to Define Treatment Success

Acute and Chronic Urticaria Diagnosis and Management Taking into Account Their Differences

Contact Info

Product

Resources

About